logo

Recursion Pharmaceuticals, Inc. (RXRX)



Trade RXRX now with
  Date
  Headline
4/11/2022 8:00:01 AM Recursion Granted Fast Track Designation For REC-4881 For Potential Treatment Of Familial Adenomatous Polyposis
3/23/2022 7:57:59 AM Recursion Q4 Total Revenue $2.5 Mln Vs $2.7 Mln Prior Year
3/18/2022 7:57:14 AM Recursion Reports Enrollment Of First Patient In Phase 2 Trial For Treatment Of Cerebral Cavernous Malformation
12/7/2021 7:59:08 AM Recursion Collaborates With Roche, Genentech In Neuroscience And Oncology
12/6/2021 7:58:09 AM Recursion, Bayer Expand Fibrosis Collaboration To Include Inferential Search Capabilities
10/7/2021 7:58:17 AM Recursion Granted FDA Fast Track Designation For REC-2282 For Potential Treatment Of NF2-Mutated Meningiomas
9/29/2021 8:57:13 AM Recursion Granted Orphan Drug Designation For REC-4881 For Potential Treatment Of Familial Adenomatous Polyposis
8/13/2021 8:05:49 AM Recursion Q2 Net Loss $43.4 Mln Vs. Loss Of $18.9 Mln Prior Year
5/25/2021 8:31:25 AM Recursion Pharma Initiates IND-enabling Studies For REC-163964 To Potentially Treat Clostridium Difficile Colitis
5/12/2021 9:42:56 AM Recursion Q1 Net Loss $30.7 Mln Vs. Net Loss $18.4 Mln Prior Year